Femasys Inc (FEMY)vsWest Pharmaceutical Services Inc (WST)
FEMY
Femasys Inc
$2.78
+1.46%
HEALTHCARE · Cap: $27.30M
WST
West Pharmaceutical Services Inc
$346.23
+0.58%
HEALTHCARE · Cap: $23.93B
Smart Verdict
WallStSmart Research — data-driven comparison
West Pharmaceutical Services Inc generates 144575% more annual revenue ($3.33B vs $2.30M). WST leads profitability with a 17.0% profit margin vs 0.0%. WST earns a higher WallStSmart Score of 61/100 (C+).
FEMY
Avoid16
out of 100
Grade: F
WST
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for FEMY.
Margin of Safety
-46.2%
Fair Value
$168.33
Current Price
$346.23
$177.90 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Strong operational efficiency at 22.5%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Elevated debt levels
Trading at 8.2x book value
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : FEMY
The strongest argument for FEMY centers on Price/Book.
Bull Case : WST
The strongest argument for WST centers on Altman Z-Score, Debt/Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 22.5%. Revenue growth of 13.8% demonstrates continued momentum.
Bear Case : FEMY
The primary concerns for FEMY are EPS Growth, Market Cap, Profit Margin.
Bear Case : WST
The primary concerns for WST are Price/Book, PEG Ratio, P/E Ratio. A P/E of 43.5x leaves little room for execution misses.
Key Dynamics to Monitor
FEMY profiles as a value stock while WST is a mature play — different risk/reward profiles.
WST carries more volatility with a beta of 1.14 — expect wider price swings.
WST is growing revenue faster at 13.8% — sustainability is the question.
WST generates stronger free cash flow (81M), providing more financial flexibility.
Bottom Line
WST scores higher overall (61/100 vs 16/100), backed by strong 17.0% margins and 13.8% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Femasys Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Femasys Inc. is a pioneering medical technology company focused on revolutionizing women's healthcare with its proprietary, non-surgical solutions for diagnosing and treating gynecological conditions, including uterine fibroids and contraception. By addressing significant unmet needs in women's health, Femasys is positioned to benefit from the growing demand for minimally invasive treatments, which enhance patient outcomes and improve healthcare efficiency. The company's innovative approach aims to set new standards of care, reinforcing its commitment to transforming the landscape of women's health and solidifying its role as a key player in this vital and expanding market.
West Pharmaceutical Services Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?